Research performed by scientists at the School of Biomedical and Molecular Sciences, University of Surrey and the Health Protection Agency (Porton Down, Salisbury) provides hope for developing a new meningitis vaccine that will protect children against all groups of meningococcus.
Published in the journal, Infection and Immunity, the research found that meningococcus is responsible for epidemics of meningitis worldwide that kills thousands of children each year. Vaccines are available for the A and C groups, but no effective vaccine is currently available for B groups. There are about 1500 confirmed cases of group B meningitis in the UK each year, but the true incidence is likely to be nearer twice that number since many cases go unreported. About 10% of children who suffer meningococcal meningitis die of the disease and many of the survivors are left severely handicapped.
The Surrey researchers used genetic engineering technology to make a mutant group of the meningococcus that was incapable of causing disease in mice. The mutant was made in a C group of the meningococcus. However, mice that were inoculated with the mutant group developed antibodies that killed not only C groups but also B and A groups. It appears that, by inoculating with the disabled group, the mice have effectively been immunised against all groups.
Liezel Tipper | alfa
Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University
ASU scientists develop new, rapid pipeline for antimicrobials
14.12.2017 | Arizona State University
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
14.12.2017 | Health and Medicine
14.12.2017 | Physics and Astronomy
14.12.2017 | Life Sciences